TY - JOUR
T1 - The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer
AU - Lee, Chung Ta
AU - Chow, Nan Haw
AU - Su, Pei Fang
AU - Lin, Shao Chieh
AU - Lin, Peng Chan
AU - Lee, Jenq Chang
N1 - Funding Information:
Supported by grants NSC94–2314-B-006–058 from the National Science Council and DOH-TD-B-111–004 from the Department of Health, Executive Yuan, Taiwan. Poster presentation at the 11th Congress of Asian Federation of Coloproctology, Tokyo, Japan, September 20 to 22, 2007. Address of correspondence: Jenq-Chang Lee, M.D., Department of Surgery, National Cheng Kung University of Hospital, 138 Sheng-Li Road, Tainan 704, Taiwan. E-mail: [email protected]
PY - 2008/8
Y1 - 2008/8
N2 - PURPOSE: Although Recepteur d'Origine Nantais (RON), a member of the MET receptor tyrosine kinase family, is overexpressed and constitutively active in some primary tumors and tumor cell lines, its expression pattern and clinical significance in colorectal cancer are not well documented. METHODS: By using immunohistochemical staining, we examined RON and MET expression in 135 colorectal cancer specimens and investigated the association of the immunoreactivity of both receptors with colorectal cancer clinical parameters and prognosis. RESULTS: We found moderate to strong expression in 99 cases (73 percent) for RON and 97 cases (72 percent) for MET. Univariate analysis showed that increased immunoreactivity of RON or MET was associated with shorter patient survival and that moderate to strong coexpression of both receptors was associated with a significantly worse prognosis. Multivariate Cox analysis showed that the risk of tumor recurrence for patients with high-RON/high-MET expression was approximately 11 times greater than for patients with low-RON/low-MET expression (P=0.001). In addition, RON and MET expression levels were positively correlated (P≤0.001; τ=0.306). CONCLUSIONS: The crosstalk between RON and MET in colorectal cancer seems important. Evaluating the expression patterns of RON and MET was predictive of clinical outcome for patients with colorectal cancer.
AB - PURPOSE: Although Recepteur d'Origine Nantais (RON), a member of the MET receptor tyrosine kinase family, is overexpressed and constitutively active in some primary tumors and tumor cell lines, its expression pattern and clinical significance in colorectal cancer are not well documented. METHODS: By using immunohistochemical staining, we examined RON and MET expression in 135 colorectal cancer specimens and investigated the association of the immunoreactivity of both receptors with colorectal cancer clinical parameters and prognosis. RESULTS: We found moderate to strong expression in 99 cases (73 percent) for RON and 97 cases (72 percent) for MET. Univariate analysis showed that increased immunoreactivity of RON or MET was associated with shorter patient survival and that moderate to strong coexpression of both receptors was associated with a significantly worse prognosis. Multivariate Cox analysis showed that the risk of tumor recurrence for patients with high-RON/high-MET expression was approximately 11 times greater than for patients with low-RON/low-MET expression (P=0.001). In addition, RON and MET expression levels were positively correlated (P≤0.001; τ=0.306). CONCLUSIONS: The crosstalk between RON and MET in colorectal cancer seems important. Evaluating the expression patterns of RON and MET was predictive of clinical outcome for patients with colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=48349119885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48349119885&partnerID=8YFLogxK
U2 - 10.1007/s10350-008-9297-1
DO - 10.1007/s10350-008-9297-1
M3 - Article
C2 - 18536971
AN - SCOPUS:48349119885
SN - 0012-3706
VL - 51
SP - 1268
EP - 1274
JO - Diseases of the Colon and Rectum
JF - Diseases of the Colon and Rectum
IS - 8
ER -
